2025 Annual Meeting | C23 - Anti-amyloid Therapy Boot Camp

Date Saturday 04/05/25

Time 12:00 PM - 04:00 PM PDT Add To Calendar

Location San Diego Convention Center | 3

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Jonathan Graff-Radford, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should be able to appraise major findings from recent clinical trials of anti-amyloid monoclonal antibody therapies in Alzheimer's disease; understand imaging and fluid biomarkers relevant for treatment eligibility and monitoring; identify proposed clinical criteria for appropriate use of anti-amyloid therapies in clinical practice; summarize mechanisms, risk factors, and safety monitoring for amyloid-related imaging abnormalities; and assess practice-level adaptations needed for emerging AD therapies.

This program is supported in part by educational grants from Eisai Inc. and Lilly

CME Available 4.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Advanced

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
12:00 PM - 12:30 PM PDT	Speaker	Updates on Anti-amyloid Therapy Gil D. Rabinovici, MD, FAAN
12:30 PM - 12:50 PM PDT	Speaker	Updates on Appropriate Use Criteria Judith L. Heidebrink, MD
12:50 PM - 01:15 PM PDT	Speaker	Using Biomarkers in Clinic Practice Irina Skylar-Scott, MD
01:15 PM - 01:40 PM PDT	Speaker	Comparing Anti-amyloid Therapies Judith L. Heidebrink, MD
01:40 PM - 01:55 PM PDT	Q&A	Questions and Answers Jonathan Graff-Radford, MD, FAAN
01:55 PM - 02:00 PM PDT	Break	Break
02:00 PM - 02:25 PM PDT	Speaker	Case Studies in the Management of ARIA Vijay K. Ramanan, MD, PhD
02:25 PM - 02:50 PM PDT	Speaker	Cases in Evaluation of Eligibility Jonathan Graff-Radford, MD, FAAN
02:50 PM - 03:15 PM PDT	Speaker	Creating an Anti-Amyloid Program in Practice Gregory E. Cooper, MD, PhD, FAAN
03:15 PM - 03:30 PM PDT	Speaker	When to Stop Anti-amyloid Therapy? Vijay K. Ramanan, MD, PhD
03:30 PM - 04:00 PM PDT	Q&A	Questions and Answers Jonathan Graff-Radford, MD, FAAN, Vijay K. Ramanan, MD, PhD, Judith L. Heidebrink, MD, Gil D. Rabinovici, MD, FAAN, Gregory E. Cooper, MD, PhD, FAAN

Faculty Disclosures
Jonathan Graff-Radford, MD, FAAN	Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics.
Vijay K. Ramanan, MD, PhD	The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
Judith L. Heidebrink, MD	The institution of Dr. Heidebrink has received research support from Eli Lilly. The institution of Dr. Heidebrink has received research support from Eisai. The institution of Dr. Heidebrink has received research support from NIH. The institution of Dr. Heidebrink has received research support from Alzheimer's Association. The institution of Dr. Heidebrink has received research support from Cognition Therapeutics. Dr. Heidebrink has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member for the IMPACT-AD Clinical Trials course with the University of Southern California (funded by NIA/Alzheimer's Association).
Gil D. Rabinovici, MD, FAAN	Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Norodisk. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Peerview. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA.
Gregory E. Cooper, MD, PhD, FAAN	The institution of Dr. Cooper has received research support from Eli Lilly. The institution of Dr. Cooper has received research support from Davos Alzheimer's Collaborative. Dr. Cooper has a non-compensated relationship as a Consultant with Health & Wellness Partners, LLC that is relevant to AAN interests or activities.
Irina Skylar-Scott, MD	An immediate family member of Dr. Skylar-Scott has received personal compensation in the range of $500-$4,999 for serving as a Consultant for 3D Systems. The institution of an immediate family member of Dr. Skylar-Scott has received research support from The Chan Zuckerberg Initiative. Dr. Skylar-Scott has received research support from Biogen. An immediate family member of Dr. Skylar-Scott has received intellectual property interests from a discovery or technology relating to health care. Dr. Skylar-Scott has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��